Terns Pharmaceuticals Inc

NASDAQ:TERN  
7.50
-0.68 (-8.31%)
Products, Regulatory

Terns Reports Positive Top-line Results from Phase 2A LIFT Study Of TERN-101

Published: 06/14/2021 14:05 GMT
Terns Pharmaceuticals Inc (TERN) - Terns Pharmaceuticals - Reported Positive Top-line Results From Phase 2a Lift Clinical Trial of Tern-101.
Terns Pharmaceuticals Inc - Plans to Initiate First Nash Trial of an Fxr Agonist (tern-101) in Combination With a Thr-Β Agonist (tern-501) in 1h22.
Terns Pharmaceuticals - in Lift Trial, Tern-101 Was Generally Well Tolerated With Similar Incidence of Adverse Events Across Treatment Groups.
Terns Pharmaceuticals - All Treatment-related Adverse Events in Lift Trial Were Mild/moderate With No Apparent Dose Relationship.
Terns Pharmaceuticals - There Were No Treatment-related Serious Adverse Events, No Patient Discontinued Tern-101 Due to Any Adverse Event Including Pruritus.